Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 10/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 5/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24995209 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14805878 | 0.79 | ATM (0.40) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL20095971 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14806569 | 0.78 | ATM (0.43) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL10160177 | 0.76 | ATM (0.35) | ATM | |
| SCHEMBL21569686 | 0.76 | L3MBTL3 (0.40) | HSD11B1HRH3L3MBTL3PDK2 | |
| SCHEMBL26421320 | 0.75 | HRH3 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL17886895 | 0.73 | HTT (0.51) | ATMHSD11B1HRH3 | |
| SCHEMBL26419220 | 0.71 | ATM (0.37) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17281943 | 0.71 | L3MBTL3 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | ATM 2907/4885CHRNB2 4830/4885CHRNA3 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.